You are here

Database of TGA laboratory testing results

7 December 2020

Important information on the Database of TGA Laboratory testing results

Safety alerts

When we identify serious safety or quality issues with therapeutic goods, information and recommendations are posted immediately on the Safety information pages of the TGA website.

This database does NOT provide timely alerts to healthcare professionals and consumers where a serious safety or quality issue has been identified.

Results of TGA Laboratory testing are released in May and November each year. There is a minimum delay of 6 months between the testing and publication of results. This delay in publication is necessary to allow the TGA to undertake any investigations and follow-up action in response to non-complying test results.

More information on laboratory testing of therapeutic goods is available at:

TGA's laboratory testing targets the most appropriate quality and/or performance aspects relevant to the product being tested. As such, a PASS result indicates a sample has met those quality/performance requirements tested by us.

The sponsors identified in these testing results were the sponsor of the product at the time the samples were received by the TGA. This may no longer be the current sponsor for the product. The current sponsor of a therapeutic good can be found by searching the Australian Register of Therapeutic Goods (ARTG).

Many unregistered therapeutic goods tested by TGA Laboratories have no packaging, labels or distinguishable product name. In this situation the goods are identified within this database using a description of the goods followed by '(unlabelled)'. E.g. Blue and White Pills (unlabelled).

More information on laboratory testing of unregistered therapeutic goods is available at: Testing of therapeutic products

About the release of this information

While reasonable care is taken to ensure that the information is an accurate record of the results and outcomes of TGA's laboratory testing, the TGA does not guarantee or warrant the accuracy, reliability, completeness or currency of the information or its usefulness in achieving any purpose.

To the fullest extent permitted by law, including but not limited to section 61A of the Therapeutic Goods Act 1989, the TGA will not be liable for any loss, damage, cost or expense incurred in or arising by reason of any person relying on this information.

Test results

Displaying 21 - 30 of 3484

Enter a sponsor, product name or ARTG number.

Absorbent Paper Points

Release date: May-2017

Testing category: Programmed

Product type: Medical Devices

ARTG ID: 192407

Sponsor: Orien Dental Supplies

Reason for testing: Routine Compliance Testing

Result: PASS

Absorbent Points - Cell Pack

Release date: May-2017

Testing category: Programmed

Product type: Medical Devices

ARTG ID: 212094

Sponsor: Dentsply (Australia) Pty Ltd

Reason for testing: Routine Compliance Testing

Result: PASS

ACETEC 5 enalapril maleate 5mg tablet blister pack

Release date: May-2020

Testing category: Programmed

Product type: Prescription Medicines

ARTG ID: 75497

Sponsor: Alphapharm Pty Ltd

Reason for testing: Survey of a Medicine/Device Group

Result: PASS

ACICLOVIR SANDOZ aciclovir 200mg tablet blister pack

Release date: May-2018

Testing category: Programmed

Product type: Prescription Medicines

ARTG ID: 99420

Sponsor: Sandoz Pty Ltd

Reason for testing: Survey of a Medicine/Device Group

Result: PASS

ACT-HIB haemophilus type B conjugate vaccine (conjugated to tetanus protein) powder for injection vial and needle free diluent syringe

Release date: Nov-2020

Testing category: Batch release evaluation

Product type: Prescription Medicines

ARTG ID: 130161

Sponsor: Sanofi-Aventis Australia Pty Ltd

Reason for testing: Batch Release

Result: PASS

Sample number: 1912004642

Batch number: R3N331V

Expiry date: 31-Oct-2021

ACT-HIB haemophilus type B conjugate vaccine (conjugated to tetanus protein) powder for injection vial and needle free diluent syringe

Release date: Nov-2020

Testing category: Batch release evaluation

Product type: Prescription Medicines

ARTG ID: 130161

Sponsor: Sanofi-Aventis Australia Pty Ltd

Reason for testing: Batch Release

Result: PASS

Sample number: 2004001515

Batch number: T1A052V

Expiry date: 31-Dec-2021

ACT-HIB haemophilus type B conjugate vaccine (conjugated to tetanus protein) powder for injection vial and needle free diluent syringe

Release date: Nov-2020

Testing category: Batch release evaluation

Product type: Prescription Medicines

ARTG ID: 130161

Sponsor: Sanofi-Aventis Australia Pty Ltd

Reason for testing: Batch Release

Result: PASS

Sample number: 2004001516

Batch number: T1A052V

Expiry date: 31-Dec-2021

ACT-HIB haemophilus type B conjugate vaccine (conjugated to tetanus protein) powder for injection vial and needle free diluent syringe

Release date: Nov-2020

Testing category: Batch release evaluation

Product type: Prescription Medicines

ARTG ID: 130161

Sponsor: Sanofi-Aventis Australia Pty Ltd

Reason for testing: Batch Release

Result: PASS

Sample number: 1910004062

Batch number: R3D691V

Expiry date: 31-Mar-2021

ACT-HIB haemophilus type B conjugate vaccine (conjugated to tetanus protein) powder for injection vial and needle free diluent syringe

Release date: Nov-2020

Testing category: Batch release evaluation

Product type: Prescription Medicines

ARTG ID: 130161

Sponsor: Sanofi-Aventis Australia Pty Ltd

Reason for testing: Batch Release

Result: PASS

Sample number: 1910004063

Batch number: R3D691V

Expiry date: 31-Mar-2021

ACT-HIB haemophilus type B conjugate vaccine (conjugated to tetanus protein) powder for injection vial and needle free diluent syringe

Release date: Nov-2020

Testing category: Batch release evaluation

Product type: Prescription Medicines

ARTG ID: 130161

Sponsor: Sanofi-Aventis Australia Pty Ltd

Reason for testing: Batch Release

Result: PASS

Sample number: 1910004064

Batch number: R3D691V

Expiry date: 31-Mar-2021

Pages